COMMUNIQUÉS West-GlobeNewswire

-
Volta Medical Announces Presentations at Heart Rhythm Society 2024 in Boston, MA, USA
18/04/2024 -
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
18/04/2024 -
NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024
18/04/2024 -
American Shared Hospital Services Strengthens Senior Management Structure
18/04/2024 -
Panbela Announces Poster Presentation at American Association for Cancer Research:
18/04/2024 -
New Field Data Shows High Diagnostic Yield for Lung Biopsy Diagnosis Using the Galaxy System™
18/04/2024 -
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
18/04/2024 -
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
18/04/2024 -
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
18/04/2024 -
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
18/04/2024 -
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
18/04/2024 -
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
18/04/2024 -
Castellum, Inc. Announces New Strategic Alliance
18/04/2024 -
Aveanna Announces First Quarter 2024 Earnings Release Date and Conference Call
18/04/2024 -
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
18/04/2024 -
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
18/04/2024 -
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
18/04/2024 -
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
18/04/2024 -
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
18/04/2024
Pages